MAC receives recognition by BritishAmerican Business (BAB) as part of Transatlantic Growth Campaign
The Transatlantic Growth campaign (TAG) is an annual campaign that highlights and celebrates businesses that demonstrate growth and...
MAC Opens US Office/Study Site
To continue to meet the research needs of our clients and their patients across the globe, MAC Clinical Research has arrived in the...
MAC Clinical Research has been appointed to accelerate timeline of Phase I/IIa clinical trial
Small Pharma Inc., a neuro-pharmaceutical company focused on psychedelic-assisted therapy, have announced the expansion of its phase...
MHRA approve launch of DemeRX’s Phase I/IIa trial of ibogaine HCl for treatment of OUD
MAC are excited to be collaborating with DemeRx on their phase 1 trial of Opioid Use Disorder.
PRESS RELEASE: Initiator Pharma reports positive Phase IIa clinical data for IPED2015 in patients w
Initiator Pharma A/S, a clinical-stage biotech company that is developing a novel treatment of erectile dysfunction (ED), today announced...
Peter Dewland, Senior Director of Early Phase Research at MAC Clinical Research, Elected as Chair of
In recognition of 40 years devoted to early phase clinical research, Peter Dewland, BSc, MA, MBBS, FFPM, DCPSA, Senior Director of Early...
PRESS RELEASE: MAC Clinical Research expands its Global Site Network and access to patients in Aust
October 24, 2018 MANCHESTER, ENGLAND Across every clinical trial, Pharma and Biotech have a dire need to access patients in efficient...
PRESS RELEASE: MHRA Award Accreditation for MAC's Phase 1 Site
MAC Neuroscience Centre of excellence, the early phase division of MAC Clinical Research, has been awarded Accreditation from the...
MAC Opens Phase I Clinic in the Manchester Corridor
MAC Clinical Research has opened a new phase I/IIa clinic at Citylabs in Manchester, expanding its phase I services in the United...
Dr John Connell Joins MAC As Chief Research & Development Officer
We are delighted to welcome Dr John Connell to MAC who will lead our pharmacodynamic offering. Dr Connell completed his PhD at the...
